NasdaqCM:AEMD

Stock Analysis Report

Executive Summary

Aethlon Medical, Inc., a medical technology company, focuses on addressing unmet needs in health and biodefense worldwide.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Risks

  • Aethlon Medical has significant price volatility in the past 3 months.
  • Aethlon Medical is covered by less than 3 analysts.

Share Price & News

How has Aethlon Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.4%

AEMD

1.1%

US Medical Equipment

-0.5%

US Market


1 Year Return

-76.8%

AEMD

7.9%

US Medical Equipment

0.9%

US Market

AEMD underperformed the Medical Equipment industry which returned 9.7% over the past year.

AEMD underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

AEMDIndustryMarket
7 Day2.4%1.1%-0.5%
30 Day-10.4%3.1%4.8%
90 Day-24.5%3.6%2.3%
1 Year-76.8%-76.8%8.8%7.9%3.1%0.9%
3 Year-94.5%-94.5%70.9%65.8%45.5%36.0%
5 Year-95.6%-95.6%139.2%112.0%62.5%44.7%

Price Volatility Vs. Market

How volatile is Aethlon Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Aethlon Medical undervalued based on future cash flows and its price relative to the stock market?

4.56x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Aethlon Medical to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Aethlon Medical to establish if it is available at substantial discount.


Price Based on Earnings

Aethlon Medical is loss making, we can't compare its value to the US Medical Equipment industry average.

Aethlon Medical is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Aethlon Medical, we can't assess if its growth is good value.


Price Based on Value of Assets

Aethlon Medical is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Aethlon Medical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

14.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Aethlon Medical's revenue is expected to grow significantly at over 20% yearly.

Aethlon Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.

Aethlon Medical's revenue growth is expected to exceed the United States of America market average.

Unable to compare Aethlon Medical's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Aethlon Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Aethlon Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Aethlon Medical performed over the past 5 years?

15.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Aethlon Medical does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Aethlon Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Aethlon Medical's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Aethlon Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Aethlon Medical has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Aethlon Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Aethlon Medical's financial position?


Financial Position Analysis

Aethlon Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Aethlon Medical's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Aethlon Medical's level of debt (87.7%) compared to net worth is high (greater than 40%).

Aethlon Medical had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Aethlon Medical has less than a year of cash runway based on current free cash flow.

Aethlon Medical has less than a year of cash runway if free cash flow continues to grow at historical rates of 2.9% each year.


Next Steps

Dividend

What is Aethlon Medical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Aethlon Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Aethlon Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Aethlon Medical has not reported any payouts.

Unable to verify if Aethlon Medical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Aethlon Medical has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Aethlon Medical's salary, the management and board of directors tenure and is there insider trading?

4.9yrs

Average management tenure


CEO

Timothy Rodell (68yo)

0.8yrs

Tenure

US$1,000,132

Compensation

Dr. Timothy C. Rodell, Jr., M.D., FCCP has been Interim Chief Executive Officer and Director at Aethlon Medical, Inc. since December 10, 2018. Dr. Rodell is a Managing Partner of MTR, Inc. Dr. Rodell is th ...


CEO Compensation Analysis

Timothy's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Timothy to compare compensation growth.


Management Age and Tenure

4.9yrs

Average Tenure

65yo

Average Age

The tenure for the Aethlon Medical management team is about average.


Board Age and Tenure

4.0yrs

Average Tenure

70yo

Average Age

The tenure for the Aethlon Medical board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jim Joyce (57yo)

    Consultant

    • Tenure: 0.8yrs
    • Compensation: US$272.71k
  • Timothy Rodell (68yo)

    Interim CEO & Director

    • Tenure: 0.8yrs
    • Compensation: US$1.00m
  • Jim Frakes (62yo)

    CFO, Senior VP of Finance & Secretary

    • Tenure: 9yrs
    • Compensation: US$285.83k
  • Richard Tullis (74yo)

    Consultant

    • Tenure: 0yrs
  • Sunil Sawhney

    Head of Clinical Studies

    • Tenure: 14.5yrs

Board Members

  • Timothy Rodell (68yo)

    Interim CEO & Director

    • Tenure: 0.8yrs
    • Compensation: US$1.00m
  • Ed Broenniman (83yo)

    Director

    • Tenure: 20.5yrs
    • Compensation: US$79.00k
  • Nathan Levin

    Member of Extracorporeal Therapy Advisory Board

    • Tenure: 0yrs
  • Greg Kovacs

    Member of Extracorporeal Therapy Advisory Board

    • Tenure: 0yrs
  • Claudio Ronco

    Member of Extracorporeal Therapy Advisory Board

    • Tenure: 0yrs
  • Larry Cowgill

    Member of Sepsis & Inflammation Advisory Board

    • Tenure: 0yrs
  • Chuck Fisher (72yo)

    Chairman & Member of extracorporeal Therapy Advisory Board

    • Tenure: 1.8yrs
    • Compensation: US$159.00k
  • John Kellum

    Member of Extracorporeal Therapy Advisory Board

    • Tenure: 0yrs
  • Chetan Shah (50yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$78.00k
  • David Ward

    Member of Extracorporeal Therapy Advisory Board

    • Tenure: 0yrs

Company Information

Aethlon Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aethlon Medical, Inc.
  • Ticker: AEMD
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$5.450m
  • Shares outstanding: 19.94m
  • Website: https://www.aethlonmedical.com

Number of Employees


Location

  • Aethlon Medical, Inc.
  • 9365 Granite Ridge Drive
  • Suite 100
  • San Diego
  • California
  • 92123
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AEMDNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1999
EJUNBST (Boerse-Stuttgart)YesCommon StockDEEURMar 1999

Biography

Aethlon Medical, Inc., a medical technology company, focuses on addressing unmet needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/23 23:30
End of Day Share Price2019/09/23 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.